- Home
- PENG vs INBX Comparison
PENG vs INBX Comparison
Compare PENG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | INBX |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 959.2M | 999.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | PENG | INBX |
|---|---|---|
| Price | $43.59 | $133.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | $27.78 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 1.9M | 486.3K |
| Earning Date | 04-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $14.55 | N/A |
| Revenue Next Year | $16.14 | N/A |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $16.04 | $12.80 |
| 52 Week High | $39.66 | $155.29 |
Technical Indicators
Market Signals| Indicator | PENG | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 89.45 | 66.58 |
| Support Level | $22.13 | $69.30 |
| Resistance Level | N/A | $155.29 |
| Average True Range (ATR) | 2.38 | 13.75 |
| MACD | 1.25 | 0.62 |
| Stochastic Oscillator | 96.70 | 69.23 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.